5-氯-N-甲基-2-吡啶胺 | 4214-80-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氯-N-甲基-2-吡啶胺
• 中文别名: 5-氯-2-甲基氨基吡啶
• 英文名称: 5-chloro-N-methylpyridin-2-amine
• 英文别名: 5-Chlor-2-methylamino-pyridin；5-chloro-2-(methylamino)pyridine
• CAS: 4214-80-6
• 化学式: C₆H₇ClN₂
• mdl: MFCD00955783
• 分子量: 142.588
• InChiKey: KSISYWKRGRATSK-UHFFFAOYSA-N

物化性质

• 熔点：
  63-65°C
• 沸点：
  247℃
• 密度：
  1.250
• 闪点：
  103℃
• 溶解度：
  可溶于二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  3-氯磺酰基苯甲酸 、 5-氯-N-甲基-2-吡啶胺 在 吡啶 作用下， 以 乙酸乙酯 为溶剂， 以37%的产率得到3-(N-(5-chloropyridin-2-yl)-N-methylsulfamoyl)benzoic acid
  参考文献：
  名称：

  Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors

  摘要：

  Inhibitors of sirtuin-2 deacetylase (SIRT2) have been shown to be protective in various models of Huntington's disease (HD) by decreasing polyglutamine aggregation, a hallmark of HD pathology. The present study was directed at optimizing the potency of SIRT2 inhibitors containing the neuroprotective sulfobenzoic acid scaffold and improving their pharmacology. To achieve that goal, 176 analogues were designed, synthesized, and tested in deacetylation assays against the activities of major human sirtuins SIRT1-3. This screen yielded 15 compounds with enhanced potency for SIRT2 inhibition and 11 compounds having SIRT2 inhibition equal to reference compound AK-1. The newly synthesized compounds also demonstrated higher SIRT2 selectivity over SIRT1 and SIRT3. These candidates were subjected to a dose-response bioactivity assay, measuring an increase in alpha-tubulin K40 acetylation in two neuronal cell lines, which yielded five compounds bioactive in both cell lines and eight compounds bioactive in at least one of the cell lines tested. These bioactive compounds were subsequently tested in a tertiary polyglutamine aggregation assay, which identified five inhibitors. ADME properties of the bioactive SIRT2 inhibitors were assessed, which revealed a significant improvement of the pharmacological properties of the new entities, reaching closer to the goal of a clinically-viable candidate. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.02.003
• 作为产物：
  描述：

  2-<(benzotriazol-1-yl)methylamino>-5-chloropyridine 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以92%的产率得到5-氯-N-甲基-2-吡啶胺
  参考文献：
  名称：

  Katritzky, Alan R.; Rachwal, Stanislaw; Rachwal, Bogumila, Journal of the Chemical Society. Perkin transactions I, 1987, p. 805 - 810

  摘要：

  DOI：

文献信息

• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050020645A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  通用式（1）表示的化合物： Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1） 其中R1和R2是氢原子或类似物；Q1是饱和或不饱和的、5-或6-成员环烃基，可以被取代，或类似物；Q2是单键或类似物；Q3是一个基团，其中Q5是具有1至8个碳原子的烷基基团，或类似物；T0和T1是羰基团或类似物；其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成，或抽血时的血液凝结。
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES PARASITAIRES
  申请人：IRM LLC

  公开号：WO2014078813A1

  公开（公告）日：2014-05-22

  The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a Plasmodium parasite.

  本发明提供了式I的化合物：[在此插入公式]或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这种化合物的药物组合物以及使用这种化合物治疗、预防、抑制、改善或根除由疟原虫引起的疟疾等疾病的方法。
• Iridium-catalyzed enantioselective addition of an <i>N</i>-methyl C–H bond to α-trifluoromethylstyrenes <i>via</i> C–H activation
  作者：Daisuke Yamauchi、Ikumi Nakamura、Takahiro Nishimura

  DOI：10.1039/d1cc05076a

  日期：——

  Ir-catalyzed enantioselective addition of an N-methyl C–H bond of 2-(methylamino)pyridine derivatives to α-trifluoromethylstyrenes proceeded via C–H activation to give chiral γ-branched amine derivatives having a trifluoromethyl-substituted stereocenter. It was found that a bulky and electron-withdrawing group at the 3-position of 2-(methylamino)pyridines was necessary for the present C–H addition reaction

  Ir 催化的 2-（甲基氨基）吡啶衍生物的N-甲基 C-H 键与 α-三氟甲基苯乙烯的对映选择性加成通过C-H 活化进行，得到具有三氟甲基取代立体中心的手性 γ-支化胺衍生物。发现在 2-（甲基氨基）吡啶的 3-位上有一个庞大的吸电子基团，对于目前由阳离子铱/手性双膦配合物催化的 C-H 加成反应是必要的。
• [EN] BENZAMIDE COMPOUNDS AND RELATED METHODS OF USE<br/>[FR] COMPOSÉS BENZAMIDE ET LEURS PROCÉDÉS D'UTILISATION CONNEXES
  申请人：UNIV NORTHWESTERN

  公开号：WO2014100833A1

  公开（公告）日：2014-06-26

  Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.

  苯甲酰胺化合物及其衍生物，可用于选择性抑制SIRT2酶和/或在亨廷顿病的治疗中用于治疗用途。
• Optimization of triazole-based TGR5 agonists towards orally available agents
  作者：Kentaro Futatsugi、Kevin B. Bahnck、Martin B. Brenner、Joanne Buxton、Janice E. Chin、Steven B. Coffey、Jeffrey Dubins、Declan Flynn、Denise Gautreau、Angel Guzman-Perez、John R. Hadcock、David Hepworth、Michael Herr、Terri Hinchey、Ann M. Janssen、Sandra M. Jennings、Wenhua Jiao、Sophie Y. Lavergne、Bryan Li、Mei Li、Michael J. Munchhof、Suvi T. M. Orr、David W. Piotrowski、Nicole S. Roush、Matthew Sammons、Benjamin D. Stevens、Gregory Storer、Jian Wang、Joseph S. Warmus、Liuqing Wei、Angela C. Wolford

  DOI：10.1039/c2md20174g

  日期：——

  With the challenge of striking the balance of TGR5 potency and clearance, the screening strategy as well as medicinal chemistry strategy are discussed in this article.

  面对TGR5效力和清除之间的平衡挑战，本文讨论了筛选策略和药物化学策略。